申请人:Ube Industries Limited
公开号:US05288726A1
公开(公告)日:1994-02-22
Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen, alkyl, halogen, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkylthio, haloalkylthio, amino, alkanoyl, haloalkanoyl, carboxy, alkoxycarbonyl, carbamoyl, cyano, nitro, alkanesulfonyl, haloalkanesulfonyl or sulfamoyl; R.sup.2 is optionally substituted alkanoyl, optionally substituted alkenoyl, optionally substituted cycloalkylcarbonyl, substituted benzoyl, or 5,6-dihydro-1,4,2-dioxazin-3-yl; R.sup.3 is hydrogen, hydroxy, optionally substituted alkoxy, aralkyloxy, alkanoyloxy, alkenoyloxy, cycloalkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aralkyloxycarbonylxy, phthalidyloxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy, (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methoxy, optionally substituted amino or nitro; Y is --NH-- or oxygen or sulfur; n is 1 to 5; and tautomers and salts of said compounds of formula (I), have the ability to inhibit blood platelet aggregation, and can thus be used for treatment and prophylaxis of thrombosis and embolisms.
式(I)的化合物:其中:R.sup.1是氢,烷基,卤素,卤代烷基,羟基,烷氧基,卤代烷氧基,烷基硫基,卤代烷基硫基,氨基,烷酰基,卤代烷酰基,羧基,烷氧羰基,氨基甲酰基,氰基,硝基,烷基磺酰基,卤代烷基磺酰基或磺酰胺;R.sup.2是可选择取代的烷酰基,可选择取代的烯酰基,可选择取代的环烷基羰基,取代的苯甲酰基,或5,6-二氢-1,4,2-二噁唑啉-3-基;R.sup.3是氢,羟基,可选择取代的烷氧基,芳基氧基,烷酰氧基,烯酰氧基,环烷基羰氧基,芳基羰氧基,烷氧羰氧基,芳基氧羰氧基,邻苯二甲酸二酰氧基,(5-甲基-2-氧代-1,3-二氧杂环戊二烯-4-基)甲氧基,(5-苯基-2-氧代-1,3-二氧杂环戊二烯-4-基)甲氧基,可选择取代的氨基或硝基;Y是--NH--或氧或硫;n为1至5;以及式(I)的所述化合物的互变异构体和盐具有抑制血小板聚集的能力,因此可用于治疗和预防血栓形成和栓塞。